FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 330:1253-1259 May 5, 1994 Number 18 Next

	Full Text Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Adjuvant chemotherapy is widely used for breast cancer and is known to extend survival. Some clinicians seek a greater survival benefit by increasing the intensity of the dose, whereas others lower it to diminish toxicity.

Methods The Cancer and Leukemia Group B (CALGB) conducted a randomized trial of different levels of doses and dose intensity (dose per unit of time) of adjuvant chemotherapy in 1572 women with node-positive, stage II breast cancer who were assigned to three treatment groups. One group received 400 mg of cyclophosphamide per square meter of body-surface area and 40 mg of doxorubicin per square meter once every 28 days and 400 mg of fluorouracil per square meter twice every 28 days, for six cycles. Another group received 50 percent higher doses of the three drugs (600 mg, 60 mg, and 600 mg, respectively) but for only four cycles, so that the total dose was identical in these two groups but the dose intensity was higher in the second. The third group of women received half the total dose used in the other two groups and at half the dose intensity used in the second group.

Results After a median of 3.4 years of follow-up, the women treated with a high or moderate dose intensity had significantly longer disease-free survival (P<0.001) and overall survival (P = 0.004) than those treated with a low dose intensity, in three-way log-rank comparisons. However, the difference in survival between the two groups treated with a moderate or high dose intensity was not significant. These results are consistent with either a dose-response effect or a threshold level of the dose or dose intensity.

Conclusions The doses of chemotherapy used to treat breast cancer, especially early breast cancer, should not be reduced if the maximal benefit is to be achieved. .

Source Information

From the Winship Cancer Center, Emory University, Atlanta (W.C.W.); North Shore University Hospital, Manhassett, N.Y. (D.R.B.); the Department of Biostatistics, Harvard School of Public Health, Boston (A.H.K.); the Bowman Gray School of Medicine, Winston-Salem, N.C. (M.R.C., C.R.F.); Massachusetts General Hospital, Boston (J.Y.); St. Luke's Medical Center, Milwaukee (R.D.H.); New York Hospital and Cornell Medical Center, New York (A.M.); the S. Nevada Cancer Research Foundation, Las Vegas (J.A.E.); the Memorial Sloan-Kettering Cancer Center, New York (L.N.); the Frontier Science Technology and Research Foundation, Amherst, N.Y. (A.C.B.); the Dana-Farber Cancer Institute, Boston (E.F.); and the University of California, San Francisco, School of Medicine, San Francisco (I.C.H.).

Address reprint requests to Dr. Wood at the Department of Surgery, Emory University School of Medicine, 1364 Clifton Rd., N.E., Atlanta, GA 30322.

Full Text of this Article

Related Letters:

Adjuvant Therapy for Breast Cancer
Muller H.-J., Gleiter C. H., Gundert-Remy U., Melnychuk D., Panasci L. C., Coppin C. M.L., Goldie J. H., Sauter C., Garey J., Lehrer S., Farkas D. H., Umek R. M., Morrison B. W., Atkins C. D., Wood W. C., Budman D., Henderson I. C., Muss H. B., Thor A. D., Berry D. A., Goldhirsch A., Gelber R. D.
Extract | Full Text  
N Engl J Med 1994; 331:741-746, Sep 15, 1994. Correspondence

Clinical Problem-Solving: Necrotizing Fasciitis
Kaufman J. L., Korzets A., Cohen E., Zahavi I., Thibault G. E.
Extract | Full Text  
N Engl J Med 1994; 331:279-280, Jul 28, 1994. Correspondence

This article has been cited by other articles:

• DiGiovanna, M. P., Stern, D. F., Edgerton, S., Broadwater, G., Dressler, L. G., Budman, D. R., Henderson, I. C., Norton, L., Liu, E. T., Muss, H. B., Berry, D. A., Hayes, D. F., Thor, A. D. (2008). Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B. JCO 26: 2364-2372 [Abstract] [Full Text]  
• Weihs, K. L., Enright, T. M., Simmens, S. J. (2008). Close Relationships and Emotional Processing Predict Decreased Mortality in Women with Breast Cancer: Preliminary Evidence. Psychosom. Med. 70: 117-124 [Abstract] [Full Text]  
• Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., Henderson, I. C., Norton, L., Winer, E. P., Hudis, C. A., Ellis, M. J., Berry, D. A., the Cancer and Leukemia Group B (CALGB) Investiga, (2007). HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. NEJM 357: 1496-1506 [Abstract] [Full Text]  
• Courneya, K. S., Segal, R. J., Mackey, J. R., Gelmon, K., Reid, R. D., Friedenreich, C. M., Ladha, A. B., Proulx, C., Vallance, J. K.H., Lane, K., Yasui, Y., McKenzie, D. C. (2007). Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial. JCO 25: 4396-4404 [Abstract] [Full Text]  
• Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H. -J., Panel Members, (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144 [Abstract] [Full Text]  
• Ozer, H., Mirtsching, B., Rader, M., Luedke, S., Noga, S. J., Ding, B., Dreiling, L. (2007). Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use. The Oncologist 12: 484-494 [Abstract] [Full Text]  
• Linden, H. M., Haskell, C. M., Green, S. J., Osborne, C. K., Sledge, G. W. Jr, Shapiro, C. L., Ingle, J. N., Lew, D., Hutchins, L. F., Livingston, R. B., Martino, S. (2007). Sequenced Compared With Simultaneous Anthracycline and Cyclophosphamide in High-Risk Stage I and II Breast Cancer: Final Analysis From INT-0137 (S9313). JCO 25: 656-661 [Abstract] [Full Text]  
• Lohrisch, C., Paltiel, C., Gelmon, K., Speers, C., Taylor, S., Barnett, J., Olivotto, I. A. (2006). Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer. JCO 24: 4888-4894 [Abstract] [Full Text]  
• Buzdar, A. U. (2006). Topoisomerase II{alpha} Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer. JCO 24: 2409-2411 [Full Text]  
• Hudis, C. A., Winer, E. P. (2006). Cancer and leukemia group B breast committee: decades of progress and plans for the future.. Clin. Cancer Res. 12: 3576s-3580s [Abstract] [Full Text]  
• Neugut, A. I., Matasar, M., Wang, X., McBride, R., Jacobson, J. S., Tsai, W.-Y., Grann, V. R., Hershman, D. L. (2006). Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly. JCO 24: 2368-2375 [Abstract] [Full Text]  
• Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., Levine, M. N., the National Cancer Institute of Canada Clinical T, (2006). HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. NEJM 354: 2103-2111 [Abstract] [Full Text]  
• Lalami, Y., Paesmans, M., Muanza, F., Barette, M., Plehiers, B., Dubreucq, L., Georgala, A., Klastersky, J. (2006). Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 17: 507-514 [Abstract] [Full Text]  
• International Breast Cancer Study Group, (2006). Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95. JCO 24: 370-378 [Abstract] [Full Text]  
• Hutchins, L. F., Green, S. J., Ravdin, P. M., Lew, D., Martino, S., Abeloff, M., Lyss, A. P., Allred, C., Rivkin, S. E., Osborne, C. K. (2005). Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102. JCO 23: 8313-8321 [Abstract] [Full Text]  
• Papaldo, P., Lopez, M., Marolla, P., Cortesi, E., Antimi, M., Terzoli, E., Vici, P., Barone, C., Ferretti, G., Di Cosimo, S., Carlini, P., Nistico, C., Conti, F., Di Lauro, L., Botti, C., Di Filippo, F., Fabi, A., Giannarelli, D., Calabresi, F. (2005). Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. JCO 23: 6908-6918 [Abstract] [Full Text]  
• Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., Neugut, A. I. (2005). Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer. JCO 23: 6639-6646 [Abstract] [Full Text]  
• DeMichele, A., Aplenc, R., Botbyl, J., Colligan, T., Wray, L., Klein-Cabral, M., Foulkes, A., Gimotty, P., Glick, J., Weber, B., Stadtmauer, E., Rebbeck, T. R. (2005). Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort. JCO 23: 5552-5559 [Abstract] [Full Text]  
• Loi, S., Milne, R. L., Friedlander, M. L., McCredie, M. R.E., Giles, G. G., Hopper, J. L., Phillips, K.-A. (2005). Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer. Cancer Epidemiol. Biomarkers Prev. 14: 1686-1691 [Abstract] [Full Text]  
• Griggs, J. J., Sorbero, M. E. S., Lyman, G. H. (2005). Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy. Arch Intern Med 165: 1267-1273 [Abstract] [Full Text]  
• Peters, W. P., Rosner, G. L., Vredenburgh, J. J., Shpall, E. J., Crump, M., Richardson, P. G., Schuster, M. W., Marks, L. B., Cirrincione, C., Norton, L., Henderson, I.C., Schilsky, R. L., Hurd, D. D. (2005). Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13. JCO 23: 2191-2200 [Abstract] [Full Text]  
• Pierce, L. J. (2005). The Use of Radiotherapy After Mastectomy: A Review of the Literature. JCO 23: 1706-1717 [Full Text]  
• Shen, Y., Parmigiani, G. (2005). A Model-Based Comparison of Breast Cancer Screening Strategies: Mammograms and Clinical Breast Examinations. Cancer Epidemiol. Biomarkers Prev. 14: 529-532 [Abstract] [Full Text]  
• Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., Graham, M. L., Sharp, S. A., Keresztes, R., Henderson, I. C., Hudis, C., Muss, H., Norton, L. (2004). Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342. JCO 22: 2061-2068 [Abstract] [Full Text]  
• Atkins, C. D. (2004). Dose-Dense Chemotherapy As Adjuvant Treatment for Breast Cancer. JCO 22: 749-780 [Full Text]  
• Lyman, G. H., Dale, D. C., Crawford, J. (2003). Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. JCO 21: 4524-4531 [Abstract] [Full Text]  
• Hershman, D., Weinberg, M., Rosner, Z., Alexis, K., Tiersten, A., Grann, V. R., Troxel, A., Neugut, A. I. (2003). Ethnic Neutropenia and Treatment Delay in African American Women Undergoing Chemotherapy for Early-Stage Breast Cancer. JNCI J Natl Cancer Inst 95: 1545-1548 [Abstract] [Full Text]  
• Gardner, S. N., Fernandes, M. (2003). New tools for cancer chemotherapy: computational assistance for tailoring treatments. Molecular Cancer Therapeutics 2: 1079-1084 [Abstract] [Full Text]  
• Kouno, T., Katsumata, N., Mukai, H., Ando, M., Watanabe, T. (2003). Standardization of the Body Surface Area (BSA) Formula to Calculate the Dose of Anticancer Agents in Japan. Jpn J Clin Oncol 33: 309-313 [Abstract] [Full Text]  
• Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., Fleming, G., Holland, J. F., Duggan, D. B., Carpenter, J. T., Frei, E. III, Schilsky, R. L., Wood, W. C., Muss, H. B., Norton, L. (2003). Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. JCO 21: 976-983 [Abstract] [Full Text]  
• Nabholtz, J.-M. A. (2003). In Reply:. JCO 21: 1191-1192 [Full Text]  
• Baldini, E., Gardin, G., Giannessi, P. G., Evangelista, G., Roncella, M., Prochilo, T., Collecchi, P., Rosso, R., Lionetto, R., Bruzzi, P., Mosca, F., Conte, P. F. (2003). Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 14: 227-232 [Abstract] [Full Text]  
• Partridge, A. H., Avorn, J., Wang, P. S., Winer, E. P. (2002). Adherence to Therapy With Oral Antineoplastic Agents. JNCI J Natl Cancer Inst 94: 652-661 [Abstract] [Full Text]  
• Schilsky, R. L., Dressler, L. M., Bucci, D., Monovich, L., Jewell, S., Suster, S., Caligiuri, M. A., Kantoff, P. W., Compton, C. (2002). Cooperative Group Tissue Banks As Research Resources: The Cancer and Leukemia Group B Tissue Repositories. Clin. Cancer Res. 8: 943-948 [Full Text]  
• Petros, W. P., Broadwater, G., Berry, D., Jones, R. B., Vredenburgh, J. J., Gilbert, C. J., Gibbs, J. P., Colvin, O. M., Peters, W. P. (2002). Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer. Clin. Cancer Res. 8: 698-705 [Abstract] [Full Text]  
• Guidi, A. J., Berry, D. A., Broadwater, G., Helmchen, B., Bleiweiss, I. J., Budman, D. R., Henderson, I. C., Norton, L., Hayes, D. F. (2002). Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869. JCO 20: 732-742 [Abstract] [Full Text]  
• National Institutes of Health Consensus Developmen, (2001). National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001: 5-15 [Abstract] [Full Text]  
• Hortobagyi, G. N (2001). Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview. J Natl Cancer Inst Monogr 2001: 72-79 [Abstract] [Full Text]  
• Piccart, M. J, Lohrisch, C., Duchateau, L., Buyse, M. (2001). Taxanes in the Adjuvant Treatment of Breast Cancer: Why Not Yet?. J Natl Cancer Inst Monogr 2001: 88-95 [Abstract] [Full Text]  
• Partridge, A. H., Burstein, H. J., Winer, E. P. (2001). Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. J Natl Cancer Inst Monogr 2001: 135-142 [Abstract] [Full Text]  
• Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Senn, H.-J. (2001). Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. JCO 19: 3817-3827 [Full Text]  
• (2001). National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. JNCI J Natl Cancer Inst 93: 979-989 [Abstract] [Full Text]  
• Wood, W. C. (2001). Challenges Facing Clinical Research. Ann. Surg. Oncol. 8: 471-476 [Full Text]  
• Shapiro, C. L., Recht, A. (2001). Side Effects of Adjuvant Treatment of Breast Cancer. NEJM 344: 1997-2008 [Full Text]  
• Del Mastro, L., Venturini, M., Lionetto, R., Carnino, F., Guarneri, D., Gallo, L., Contu, A., Pronzato, P., Vesentini, L., Bergaglio, M., Comis, S., Rosso, R. (2001). Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. JCO 19: 2213-2221 [Abstract] [Full Text]  
• Yamauchi, H., Stearns, V., Hayes, D. F. (2001). When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer. JCO 19: 2334-2356 [Abstract] [Full Text]  
• Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., Fleming, G. F., Formenti, S., Hudis, C., Kirshner, J. J., Krause, D. A., Kuske, R. R., Langer, A. S., Sledge, G. W. Jr, Whelan, T. J., Pfister, D. G. (2001). Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology. JCO 19: 1539-1569 [Abstract] [Full Text]  
• Levine, M. N., Eisen, A. (2001). Anthracycline Adjuvant Chemotherapy: How Much Is Enough?. JCO 19: 599-601 [Full Text]  
• (2001). Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial. JCO 19: 602-611 [Abstract] [Full Text]  
• Fumoleau, P., Chauvin, F., Namer, M., Bugat, R., Tubiana-Hulin, M., Guastalla, J. P., Delozier, T., Kerbrat, P., Devaux, Y., Bonneterre, J., Filleul, A., Clavel, M. (2001). Intensification of Adjuvant Chemotherapy: 5-Year Results of a Randomized Trial Comparing Conventional Doxorubicin and Cyclophosphamide With High-Dose Mitoxantrone and Cyclophosphamide With Filgrastim in Operable Breast Cancer With 10 or More Involved Axillary Nodes. JCO 19: 612-620 [Abstract] [Full Text]  
• Yang, X.-H., Sladek, T. L., Liu, X., Butler, B. R., Froelich, C. J., Thor, A. D. (2001). Reconstitution of Caspase 3 Sensitizes MCF-7 Breast Cancer Cells to Doxorubicin- and Etoposide-induced Apoptosis. Cancer Res. 61: 348-354 [Abstract] [Full Text]  
• Carr, J. A., Havstad, S., Zarbo, R. J., Divine, G., Mackowiak, P., Velanovich, V. (2000). The Association of HER-2/neu Amplification With Breast Cancer Recurrence. Arch Surg 135: 1469-1474 [Abstract] [Full Text]  
• Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., Norton, L. (2000). HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor-Positive, Node-Positive Breast Cancer. JCO 18: 3471-3479 [Abstract] [Full Text]  
• Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro, (2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO 18: 3558-3585 [Full Text]  
• Thor, A. D., Liu, S., Edgerton, S., Moore, D. II, Kasowitz, K. M., Benz, C. C., Stern, D. F., DiGiovanna, M. P. (2000). Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer. JCO 18: 3230-3239 [Abstract] [Full Text]  
• Katz, A., Strom, E. A., Buchholz, T. A., Thames, H. D., Smith, C. D., Jhingran, A., Hortobagyi, G., Buzdar, A. U., Theriault, R., Singletary, S. E., McNeese, M. D. (2000). Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation. JCO 18: 2817-2827 [Abstract] [Full Text]  
• Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., LoBuglio, A. F. (2000). Phase I Trial of the Anti-Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y-Expressing Epithelial Tumors. JCO 18: 2282-2292 [Abstract] [Full Text]  
• Braun, S. E., Chen, K., Foster, R. G., Kim, C. H., Hromas, R., Kaplan, M. H., Broxmeyer, H. E., Cornetta, K. (2000). The CC Chemokine CK{beta}-11/MIP-3{beta}/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells. J. Immunol. 164: 4025-4031 [Abstract] [Full Text]  
• Extermann, M., Balducci, L., Lyman, G. H. (2000). What Threshold for Adjuvant Therapy in Older Breast Cancer Patients?. JCO 18: 1709-1717 [Abstract] [Full Text]  
• Peters, W. P., Dansey, R. D., Klein, J. L., Baynes, R. D. (2000). High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer. The Oncologist 5: 1-13 [Abstract] [Full Text]  
• O'Shaughnessy, J. (2000). High Dose Chemotherapy for Breast Cancer: Taking Stock. The Oncologist 5: 14-17 [Full Text]  
• Hu, W. W., Long, G. D., Stockerl-Goldstein, K. E., Johnston, L. J., Chao, N. J., Negrin, R. S., Blume, K. G. (1999). A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa, and Paclitaxel followed by Mitoxantrone, Thiotepa, and Paclitaxel with Autologous Hematopoietic Cell Support for Metastatic Breast Cancer. Clin. Cancer Res. 5: 3411-3418 [Abstract] [Full Text]  
• Gradishar, W. J. (1999). High-Dose Chemotherapy and Breast Cancer. JAMA 282: 1378-1380 [Full Text]  
• Adams, V. R, Brenner, T. L (1999). Oprelvekin (Neumega(R)). J Oncol Pharm Pract 5: 117-124 [Abstract]  
• Blumenfeld, Z., Avivi, I., Ritter, M., Rowe, J. M. (1999). Preservation of Fertility and Ovarian Function and Minimizing Chemotherapy-Induced Gonadotoxicity in Young Women. Reproductive Sciences 6: 229-239 [Abstract]  
• Clarke, K., Basser, R. L., Underhill, C., Mitchell, P., Bartlett, J., Cher, L., Findlay, M., Dalley, D., Pell, M., Byrne, M., Geldard, H., Hill, J. S., Maher, D., Fox, R. M., Green, M. D., Kaye, A. H. (1999). KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma. JCO 17: 2579-2579 [Abstract] [Full Text]  
• Jakesz, R., Hausmaninger, H., Haider, K., Kubista, E., Samonigg, H., Gnant, M., Manfreda, D., Tschurtschenthaler, G., Kolb, R., Stierer, M., Fridrik, M., Mlineritsch, B., Steindorfer, P., Mittlbock, M., Steger, G. (1999). Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node-Positive Breast Cancer. JCO 17: 1701-1701 [Abstract] [Full Text]  
• Parmigiani, G., Berry, D. A., Winer, E. P., Tebaldi, C., Iglehart, J. D., Prosnitz, L. R. (1999). Is Axillary Lymph Node Dissection Indicated for Early-Stage Breast Cancer? A Decision Analysis. JCO 17: 1465-1465 [Abstract] [Full Text]  
• Hudis, C., Fornier, M., Riccio, L., Lebwohl, D., Crown, J., Gilewski, T., Surbone, A., Currie, V., Seidman, A., Reichman, B., Moynahan, M., Raptis, G., Sklarin, N., Theodoulou, M., Weiselberg, L., Salvaggio, R., Panageas, K.S., Yao, T.J., Norton, L. (1999). 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study. JCO 17: 1118-1118 [Abstract] [Full Text]  
• Basser, R. L., To, L. B., Collins, J. P., Begley, C. G., Keefe, D., Cebon, J., Bashford, J., Durrant, S., Szer, J., Kotasek, D., Juttner, C. A., Russell, I., Maher, D. W., Olver, I., Sheridan, W. P., Fox, R. M., Green, M. D. (1999). Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up. JCO 17: 82-82 [Abstract] [Full Text]  
• Hudis, C., Seidman, A., Baselga, J., Raptis, G., Lebwohl, D., Gilewski, T., Moynahan, M., Sklarin, N., Fennelly, D., Crown, J. P.A., Surbone, A., Uhlenhopp, M., Riedel, E., Yao, T. J., Norton, L. (1999). Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy. JCO 17: 93-93 [Abstract] [Full Text]  
• Subramanyan, S., Kennedy, M. J. (1998). Breast Cancer: High-Dose Therapy. The Oncologist 3: 289-299 [Abstract] [Full Text]  
• Esteva, F. J., Hortobagyi, G. N. (1998). Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. The Oncologist 3: 300-313 [Abstract] [Full Text]  
• Foote, M. (1998). The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice?. The Oncologist 3: 365-368 [Full Text]  
• Hudis, C. A., Norton, L. (1997). Adjuvant Drug Treatment for Resectable Breast Cancer. The Oncologist 2: 351-358 [Abstract] [Full Text]  
• Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., Kjaer, M., Gadeberg, C. C., Mouridsen, H. T., Jensen, M.-B., Zedeler, K., The Danish Breast Cancer Cooperative Group 82b Tri, (1997). Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy. NEJM 337: 949-955 [Abstract] [Full Text]  
• LeLorier, J., Gregoire, G., Benhaddad, A., Lapierre, J., Derderian, F. (1997). Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials. NEJM 337: 536-542 [Abstract] [Full Text]  
• Basser, R. L., Rasko, J. E.J., Clarke, K., Cebon, J., Green, M. D., Grigg, A. P., Zalcberg, J., Cohen, B., O'Byrne, J., Menchaca, D. M., Fox, R. M., Begley, C. G. (1997). Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer. Blood 89: 3118-3128 [Abstract] [Full Text]  
• Smith, M., Abrams, J., Trimble, E. L., Ungerleider, R. S. (1996). Dose Intensity of Chemotherapy for Childhood Cancers. The Oncologist 1: 293-304 [Abstract] [Full Text]  
• Recht, A., Come, S. E., Henderson, I. C., Gelman, R. S., Silver, B., Hayes, D. F., Shulman, L. N., Harris, J. R. (1996). The Sequencing of Chemotherapy and Radiation Therapy after Conservative Surgery for Early-Stage Breast Cancer. NEJM 334: 1356-1361 [Abstract] [Full Text]  
• Valero, V., Buzdar, A. U., Hortobagyi, G. N. (1996). Locally Advanced Breast Cancer. The Oncologist 1: 8-17 [Abstract] [Full Text]  
• Brockstein, B., Williams, S. (1996). High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow. Stem Cells 14: 79-89 [Abstract]  
• Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., Brambilla, C. (1995). Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer -- The Results of 20 Years of Follow-Up. NEJM 332: 901-906 [Abstract] [Full Text]  
• Muller, H.-J., Gleiter, C. H., Gundert-Remy, U., Melnychuk, D., Panasci, L. C., Coppin, C. M.L., Goldie, J. H., Sauter, C., Garey, J., Lehrer, S., Farkas, D. H., Umek, R. M., Morrison, B. W., Atkins, C. D., Wood, W. C., Budman, D., Henderson, I. C., Muss, H. B., Thor, A. D., Berry, D. A., Goldhirsch, A., Gelber, R. D. (1994). Adjuvant Therapy for Breast Cancer. NEJM 331: 741-746 [Full Text]  
• Wood, W. C. (1994). Audit of Cancer and Leukemia Group B Data. NEJM 331: 279-279 [Full Text]  
• (1994). DOSE-RESPONSE TO ADJUVANT CHEMOTHERAPY IN BREAST CANCER. JWatch General 1994: 1-1 [Full Text]  
• Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., Henderson, I. C. (1994). c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer. NEJM 330: 1260-1266 [Abstract] [Full Text]  
• Goldhirsch, A., Gelber, R. D. (1994). Understanding Adjuvant Chemotherapy for Breast Cancer. NEJM 330: 1308-1309 [Full Text]